Bladder drug repurposed to fight ALS in new trial
NCT ID NCT06249867
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether darifenacin, a drug currently used for overactive bladder, can help people with ALS. The study will enroll 30 adults aged 18-85 with confirmed ALS. Participants will take either darifenacin or a placebo daily for 24 weeks. The goal is to see if the drug is safe and can improve nerve-muscle connections, potentially slowing the disease and improving quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darifenacin (a drug used for overactive bladder, repurposed here)
What this could lead to
If it works, this could point toward a treatment that slows ALS progression and improves muscle function and quality of life.
What could go wrong
This is a small, early-phase trial with only 30 participants. The drug may not show benefit or could cause side effects. Results may not apply to all ALS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montreal Neurological Institute
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, K1Y 4E9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact